Nervous System News and Research

Latest Nervous System News and Research

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

3 Dec 2009

Study shows CIMT may be effective for treating hemiplegic cerebral palsy, but calls for more research

Constraint-induced movement therapy (CIMT) is a potentially effective form of intervention for children with hemiplegic cerebral palsy, but more research is needed, according to a new systematic review published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Cephalon's lawsuit against Teva Pharmaceuticals for patent infringement of NUVIGIL tablets

Cephalon, Inc. today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV].

3 Dec 2009

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

AANS and CNS join other surgical organizations to oppose 'Patient Protection and Affordable Care Act'

The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) have joined 17 other surgical organizations in opposing the “Patient Protection and Affordable Care Act” introduced by Senate Majority Leader Harry Reid.

2 Dec 2009

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the further extension of their research and development collaboration through 2011. This latest extension increases the collaboration term to seven years and brings the total committed funding to approximately $90 million.

2 Dec 2009

Research study on the function of orexin neurons in brain

Japanese research group led by Professor Yasuhiko Minokoshi and Dr. Tetsuya Shiuchi, scientists at the National Institute for Physiological Sciences, NIPS, Japan, found that meals stimulated with sweet taste and motivated with its anticipation regularly activates "orexin" in the brain and it stimulates muscle glucose metabolism via the sympathetic nervous system, thereby reducing blood glucose level in mice.

2 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

Sanofi-Aventis Canada and Intelliject sign license agreement

Sanofi-aventis Canada has announced a licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S and Canada).

1 Dec 2009

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

New research in the Journal of Leukocyte Biology shows the link between the nervous and immune systems and how breaking that link might lead to new treatments for a wide range of autoimmune disorders

1 Dec 2009

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).

1 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

Americans living in the Southern region may have elevated risk of dying from stroke

The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.

1 Dec 2009

QRxPharma commences Phase 3 pivotal trial of MoxDuo IR

QRxPharma Limited announced today, as part of its Phase 3 program, the initiation of a registration (also called pivotal) trial (Study 008) comparing efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete dosing by close of Q2 2010.

30 Nov 2009

Nervous System News and Research

Latest Nervous System News and Research

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Study shows CIMT may be effective for treating hemiplegic cerebral palsy, but calls for more research

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

AclarusDx Alzheimer’s test now available as RUO product

Cephalon's lawsuit against Teva Pharmaceuticals for patent infringement of NUVIGIL tablets

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

New approach to identify molecules that prevent immune cells from attacking body

AANS and CNS join other surgical organizations to oppose 'Patient Protection and Affordable Care Act'

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Research study on the function of orexin neurons in brain

Glutamatergic nerve cells regularly generated in the brain

Sanofi-Aventis Canada and Intelliject sign license agreement

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

Americans living in the Southern region may have elevated risk of dying from stroke

QRxPharma commences Phase 3 pivotal trial of MoxDuo IR

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Nervous System News and Research

Latest Nervous System News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in